Baillie Gifford's position in Recursion Pharmaceuticals is currently worth $90M. That's 0.07% of their equity portfolio (126th largest holding). The investor owns 5.60% of the outstanding Recursion Pharmaceuticals stock. The first Recursion Pharmaceuticals trade was made in Q2 2021. Since then Baillie Gifford bought shares five more times and sold shares on fourteen occasions. The investor's estimated purchase price is $593M, resulting in a loss of 85%.